Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX
Founder-led company
Catalyst Pharmaceuticals stock price today
$20.16
-1.30
-6.1%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Catalyst Pharmaceuticals stock price monthly change
+29.49%
month
Catalyst Pharmaceuticals stock price quarterly change
+29.49%
quarter
Catalyst Pharmaceuticals stock price yearly change
+24.18%
year
Catalyst Pharmaceuticals key metrics
Market Cap | 2.53B |
Enterprise value | 1.51B |
P/E | 22.79 |
EV/Sales | 4.89 |
EV/EBITDA | 10.01 |
Price/Sales | 5.84 |
Price/Book | 6.03 |
PEG ratio | 0.20 |
EPS | 0.60 |
Revenue | 411.34M |
EBITDA | 114.04M |
Income | 65.11M |
Revenue Q/Q | 15.39% |
Revenue Y/Y | 60.38% |
Profit margin | 38% |
Oper. margin | 47.61% |
Gross margin | 84.56% |
EBIT margin | 47.61% |
EBITDA margin | 27.72% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCatalyst Pharmaceuticals stock price history
Catalyst Pharmaceuticals stock forecast
Catalyst Pharmaceuticals financial statements
| Jun 2023 | 99.58M | 37.76M | 37.92% |
|---|---|---|---|
| Sep 2023 | 102.68M | -30.76M | -29.96% |
| Dec 2023 | 110.56M | 34.84M | 31.51% |
| Mar 2024 | 98.50M | 23.27M | 23.63% |
| Mar 2024 | 98.50M | 23.27M | 23.63% |
|---|---|---|---|
| Sep 2025 | 139.35M | 39.81M | 28.57% |
| Oct 2025 | 137.19M | 41.13M | 29.98% |
| Dec 2025 | 146.39M | 46.48M | 31.75% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 443896000 | 68.60M | 15.45% |
|---|---|---|---|
| Sep 2023 | 413211000 | 64.66M | 15.65% |
| Dec 2023 | 471907000 | 84.02M | 17.81% |
| Mar 2024 | 646676000 | 85.26M | 13.18% |
| Jun 2023 | 30.75M | 0 | -214K |
|---|---|---|---|
| Sep 2023 | 45.12M | -92.81M | -10.12M |
| Dec 2023 | 55.64M | -38.31M | -665K |
| Mar 2024 | 31.92M | -199K | 141.04M |
Catalyst Pharmaceuticals alternative data
| Aug 2023 | 82 |
|---|---|
| Sep 2023 | 82 |
| Oct 2023 | 82 |
| Nov 2023 | 82 |
| Dec 2023 | 82 |
| Jan 2024 | 82 |
| Feb 2024 | 82 |
| Mar 2024 | 167 |
| Apr 2024 | 167 |
| May 2024 | 167 |
| Jun 2024 | 167 |
| Jul 2024 | 167 |
Catalyst Pharmaceuticals other data
68.42%
-1.09%
of CPRX is owned by hedge funds
205
+23
74.76M
-1.03M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 25000 |
| Apr 2024 | 0 | 25000 |
| Jun 2024 | 0 | 110197 |
| Aug 2024 | 0 | 301058 |
| Nov 2024 | 0 | 880756 |
| Dec 2024 | 0 | 50000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Patrick J. McEnany (1947) Co-Founder, Chairman, Pres & Chief Executive Officer | $928,180 |
Dr. Steven R. Miller (1962) Chief Operating Officer & Chief Scientific Officer | $667,170 |
| Dr. Gary Ingenito (1956) Chief Medical & Regulatory Officer | $639,290 |
| Ms. Alicia Grande (1971) Chief Accounting Officer, Vice President, Treasurer & Chief Financial Officer | $558,270 |
| Mr. Jeffrey Del Carmen (1971) Chief Commercial Officer | $507,960 |
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity
Catalyst Pharmaceuticals: Expecting Higher FIRDAPSE Revenues In A Year
Catalyst Pharmaceuticals: A New Catalyst Tilts The Scales - Just Barely
Catalyst Pharmaceuticals: Cheap For A Reason
Catalyst Pharmaceuticals: Fixing Its Misnomer Is No Easy Task
Catalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A Thread
Catalyst Pharmaceuticals: A One-Hit Wonder With Upside
Defense Is The Best Offense: 3 Stocks To Buy
-
What's the price of Catalyst Pharmaceuticals stock today?
One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $20.16.
-
When is Catalyst Pharmaceuticals's next earnings date?
Unfortunately, Catalyst Pharmaceuticals's (CPRX) next earnings date is currently unknown.
-
Does Catalyst Pharmaceuticals pay dividends?
No, Catalyst Pharmaceuticals does not pay dividends.
-
How much money does Catalyst Pharmaceuticals make?
Catalyst Pharmaceuticals has a market capitalization of 2.53B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 85.9% to 398.2M US dollars.
-
What is Catalyst Pharmaceuticals's stock symbol?
Catalyst Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CPRX".
-
What is Catalyst Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Catalyst Pharmaceuticals?
Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Catalyst Pharmaceuticals's key executives?
Catalyst Pharmaceuticals's management team includes the following people:
- Mr. Patrick J. McEnany Co-Founder, Chairman, Pres & Chief Executive Officer(age: 78, pay: $928,180)
- Dr. Steven R. Miller Chief Operating Officer & Chief Scientific Officer(age: 63, pay: $667,170)
- Dr. Gary Ingenito Chief Medical & Regulatory Officer(age: 69, pay: $639,290)
- Ms. Alicia Grande Chief Accounting Officer, Vice President, Treasurer & Chief Financial Officer(age: 54, pay: $558,270)
- Mr. Jeffrey Del Carmen Chief Commercial Officer(age: 54, pay: $507,960)
-
Is Catalyst Pharmaceuticals founder-led company?
Yes, Catalyst Pharmaceuticals is a company led by its founder Mr. Patrick J. McEnany.
-
How many employees does Catalyst Pharmaceuticals have?
As Jul 2024, Catalyst Pharmaceuticals employs 167 workers.
-
When Catalyst Pharmaceuticals went public?
Catalyst Pharmaceuticals, Inc. is publicly traded company for more then 18 years since IPO on 8 Nov 2006.
-
What is Catalyst Pharmaceuticals's official website?
The official website for Catalyst Pharmaceuticals is catalystpharma.com.
-
Where are Catalyst Pharmaceuticals's headquarters?
Catalyst Pharmaceuticals is headquartered at 355 Alhambra Circle, Coral Gables, FL.
-
How can i contact Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals's mailing address is 355 Alhambra Circle, Coral Gables, FL and company can be reached via phone at +30 54203200.
Catalyst Pharmaceuticals company profile:
Catalyst Pharmaceuticals, Inc.
catalystpharma.comExchange:
NASDAQ
Full time employees:
167
Industry:
Biotechnology
Sector:
Healthcare
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
355 Alhambra Circle
Coral Gables, FL 33134
Coral Gables, FL 33134
CIK: 0001369568
ISIN: US14888U1016
CUSIP: 14888U101
